The Impact of the COVID-19 Pandemic on Testicular Cancer

COVID-19 Clinical Trial

Official title:

The Impact of the COVID-19 Pandemic on Oncologic Outcomes of Testicular Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05083143
• Other study ID #: COVIDTC2021
• Status: Completed
• Start date: July 1, 2021
• Est. completion date: March 25, 2022

Study information

• Verified date: April 2022
• Source: Ankara Training and Research Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In this study, investigators aim to reveal how the COVID-19 pandemic process affects testicular cancer presentations, tumor stages, the time elapsed between diagnosis and intervention, tumor recurrence and progression, which are oncological outcomes.

Description:

The rapid spread of the 2019 coronavirus disease (COVID-19) caused by a novel betacoronavirus known as the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has had dramatic effects on individuals and health systems around the world. Beyond those infected with SARS-CoV-2,the intense demand for limited health system resources has led to reduced capacity, rapid depletion of healthcare systems and hospitals becoming a source of virus transmission.

Urology associations and reference centers have issued recommendations to inform urology care during the COVID-19 outbreak. It is essential that urologists give priority to patient safety. Potential delays in the diagnosis and treatment of urological conditions and the additional burden on healthcare resources must be balanced against the risks of exposure to COVID-19. While this situation aims to conserve healthcare resources, it has created the risk of delaying cancer treatment. As a result, the transformation of health services and the increasing interest of the public in avoiding exposure to the disease has led to a decrease in the number of hospital admissions.

The effects of the pandemic on patients with testicular cancer due to a decrease in emergency room and urology clinic admissions are not clear. During theCOVID-19 outbreak, the EAU (European Association of Urology) panel of testicular cancer published an evidence-based guideline. According to this guideline, four priority groups were formed and a certain period of delaying treatment was defined for patients in each group according to their priorities.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: March 25, 2022
• Est. primary completion date: March 15, 2022
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients diagnosed with testicular cancer in the urology clinic.

Exclusion Criteria:

• Previous history of genitourinary system tumor

• Previous history of radiotherapy or chemotherapy

Related Conditions & MeSH terms

• COVID-19
• Testicular Cancer
• Testicular Neoplasms

Intervention

Behavioral:
• COVID-19 pandemic
Patients diagnosed with testicular cancer in the urology clinic during and before the COVID-19 pandemic will be retrospectively evaluated and compared.

Locations

Country	Name	City	State
Turkey	Ankara Training and Research Hospital	Ankara	Altindag

Sponsors (1)

Lead Sponsor	Collaborator
Ankara Training and Research Hospital

Country where clinical trial is conducted

Turkey, 

References & Publications (3)

Moul JW, Paulson DF, Dodge RK, Walther PJ. Delay in diagnosis and survival in testicular cancer: impact of effective therapy and changes during 18 years. J Urol. 1990 Mar;143(3):520-3. — View Citation

Wallis CJD, Novara G, Marandino L, Bex A, Kamat AM, Karnes RJ, Morgan TM, Mottet N, Gillessen S, Bossi A, Roupret M, Powles T, Necchi A, Catto JWF, Klaassen Z. Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. Eur Urol. 2020 Jul;78(1):29-42. doi: 10.1016/j.eururo.2020.04.063. Epub 2020 May 3. Review. — View Citation

Yue H, Bai X, Wang J, Yu Q, Liu W, Pu J, Wang X, Hu J, Xu D, Li X, Kang N, Li L, Lu W, Feng T, Ding L, Li X, Qi X; Gansu Provincial Medical Treatment Expert Group of COVID-19. Clinical characteristics of coronavirus disease 2019 in Gansu province, China. Ann Palliat Med. 2020 Jul;9(4):1404-1412. doi: 10.21037/apm-20-887. Epub 2020 Jul 13. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of tumor stages	Rate of tumor stages in patients who diagnosed with testicular cancer	2 month